Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Î " 9-Tetrahydrocannabinol

Neuropsychopharmacology

Volumn 43, Issue 1, 2018, Pages 142-154

  Boggs, Douglas L ^a,b   Nguyen, Jacques D ^c   Morgenson, Daralyn ^b   Taffe, Michael A ^c   Ranganathan, Mohini ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID; DRONABINOL; ENDOCANNABINOID; NABIXIMOLS; CANNABINOID RECEPTOR AGONIST;

ANTINOCICEPTION; ANXIETY; ANXIETY DISORDER; ASSOCIATION; AVERSION; COGNITION; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL HYPOACTIVITY; HUMAN; INDUCED HYPOTHERMIA; NEUROIMAGING; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; REWARD; SPECIES DIFFERENCE; ANIMAL; DRUG INTERACTION;

ANIMALS; CANNABIDIOL; CANNABINOID RECEPTOR AGONISTS; DRONABINOL; DRUG INTERACTIONS; HUMANS;

EID: 85036632991     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2017.209     Document Type: Review

References (154)

1. Adams R, Hunt M, Clark JH (1940). Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc 62: 196-200.
2. Ali SF, Newport GD, Scallet AC, Paule MG, Bailey JR, Slikker W Jr (1991). Chronic marijuana smoke exposure in the rhesus monkey. IV: Neurochemical effects and comparison to acute and chronic exposure to delta-9-tetrahydrocannabinol (THC) in rats. Pharmacol Biochem Behav 40: 677-682.
3. Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, et al (2009). Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: A double-blind, placebo controlled, crossover study. Clin Neuropharmacol 32: 41-47.
4. Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, et al (2017). Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172: 9-13.
5. Badowski ME (2017). A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: A focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol (doi:10.1007/s00280-017-3387-5; e-pub ahead of print).
6. Bhattacharyya S, Falkenberg I, Martin-Santos R, Atakan Z, Crippa JA, Giampietro V, et al (2015). Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology 40: 1343-1352.
7. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764-774.
8. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al (2001). Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852.
9. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, et al (2008). Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: Effects during response inhibition. Biol Psychiatry 64: 966-973.
10. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ (1995). Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23: 825-831.
11. Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR (2015). Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): Selectivity to limbic striatum. Psychopharmacology 232: 2723-2729.
12. Brady KT, Balster RL (1980). The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys. Psychopharmacology 72: 21-26.
13. Burgdorf JR, Kilmer B, Pacula RL (2011). Heterogeneity in the composition of marijuana seized in California. Drug Alcohol Depend 117: 59-61.
14. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008). CB2 receptors in the brain: Role in central immune function. Br J Pharmacol 153: 240-251.
15. Callaway J (2004). Hempseed as a nutritional resource: An overview. Euphytica 140: 65-72.
16. Campos AC, Guimaraes FS (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 199: 223-230.
17. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond Ser B Biol Sci 367: 3364-3378.
18. Cesamet (package insert) (2013) Meda Pharmaceuticals Inc.: Somerset, NJ, USA.
19. Cooper ZD, Haney M (2016). Sex-dependent effects of cannabis-induced analgesia. Drug Alcohol Depend 167: 112-120.
20. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, addiction. Biol Psychiatry 57: 594-608.
21. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
22. De Petrocellis L, Di Marzo V (2010). Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, synthetic cannabimimetics: Focus on G-proteincoupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 5: 103-121.
23. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613.
24. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
25. ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa LPhytocannabinoids. A. Douglas Kinghorn, Heinz Falk, Simon Gibbons, Jun'ichi Kobayashi (eds). Springer: Switzerland, 2017, pp 1-36.
26. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al (2013a). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampaldependent memory impairment. J Psychopharmacol 27: 19-27.
27. Fadda P, Robinson L, Fratta W, Pertwee RG, Riedel G (2004). Differential effects of THC-or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47: 1170-1179.
28. Farkas I, Kallo I, Deli L, Vida B, Hrabovszky E, Fekete C, et al (2010). Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons. Endocrinology 151: 5818-5829.
29. Fernandes M, Schabarek A, Coper H, Hill R (1974). Modification of delta9-THCactions by cannabinol and cannabidiol in the rat. Psychopharmacologia 38: 329-338.
30. Finn DP, Beckett SR, Roe CH, Madjd A, Fone KC, Kendall DA, et al (2004). Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci 19: 678-686.
31. Fogaca MV, Reis FM, Campos AC, Guimaraes FS (2014). Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: Involvement of 5HT1A receptors and previous stressful experience. Eur Neuropsychopharmacol 24: 410-419.
32. Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S, et al (2010). Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 13: 421-432.
33. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al (2009). Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66: 95-105.
34. Gaoni Y, Mechoulam R (1964). Isolation, structure, partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
35. Gomes FV, Reis DG, Alves FH, Correa FM, Guimaraes FS, Resstel LB (2012). Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors. J Psychopharmacol 26: 104-113.
36. Grunfeld Y, Edery H (1969). Psychopharmacological activity of the active constituents of hashish and some related cannabinoids. Psychopharmacology 14: 200-210.
37. Hampson RE, Miller F, Palchik G, Deadwyler SA (2011). Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: Implications for endocannabinoid control of hippocampal neural plasticity. Neuropharmacology 60: 944-952.
38. Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, et al (2016). Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology 41: 1974-1982.
39. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW (2001). Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25: 757-765.
40. Hashimotodani Y, Ohno-Shosaku T, Kano M (2007). Endocannabinoids and synaptic function in the CNS. Neuroscientist 13: 127-137.
41. Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, et al (2008). Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res 1188: 157-164.
42. Heishman SJ, Huestis MA, Henningfield JE, Cone EJ (1990). Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, performance measures. Pharmacol Biochem Behav 37: 561-565.
43. Heyser CJ, Hampson RE, Deadwyler SA (1993). Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 264: 294-307.
44. Hiltunen AJ, Jarbe TU (1986). Interactions between delta 9-tetrahydrocannabinol and cannabidiol as evaluated by drug discrimination procedures in rats and pigeons. Neuropharmacology 25: 133-142.
45. Hiltunen AJ, Jarbe TU, Wangdahl K (1988). Cannabinol and cannabidiol in combination: Temperature, open-field activity, vocalization. Pharmacol Biochem Behav 30: 675-678.
46. Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, et al (2015). Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 25: 325-334.
47. Hooker WD, Jones RT (1987). Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication. Psychopharmacology 91: 20-24.
48. Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, et al (2007). Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology 194: 505-515.
49. Hunt CA, Jones RT, Herning RI, Bachman J (1981). Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 9: 245-260.
50. Hyman SM, Sinha R (2009). Stress-related factors in cannabis use and misuse: Implications for prevention and treatment. J Subst Abuse Treat 36: 400-413.
51. Iseger TA, Bossong MG (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162: 153-161.
52. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009). Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
53. Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, et al (2016). Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proc Natl Acad Sci USA 113: E500-E508.
54. Jacobs DS, Kohut SJ, Jiang S, Nikas SP, Makriyannis A, Bergman J (2016). Acute and chronic effects of cannabidiol on Delta(9)-tetrahydrocannabinol (Delta(9)-THC)-induced disruption in stop signal task performance. Exp Clin Psychopharmacol 24: 320-330.
55. John WS, Martin TJ, Nader MA (2017). Behavioral determinants of cannabinoid self-administration in old world monkeys. Neuropsychopharmacology 42: 1522-1530.
56. Justinova Z, Goldberg SR, Heishman SJ, Tanda G (2005). Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 81: 285-299.
57. Justinova Z, Panlilio LV, Moreno-Sanz G, Redhi GH, Auber A, Secci ME, et al (2015). Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse. Neuropsychopharmacology 40: 2185-2197.
58. Justinova Z, Tanda G, Munzar P, Goldberg SR (2004). The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl) 173: 186-194.
59. Justinova Z, Tanda G, Redhi GH, Goldberg SR (2003). Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl) 169: 135-140.
60. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974). Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28: 172-177.
61. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA (2011a). Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 57: 66-75.
62. Karschner EL, Darwin WD, McMahon RP, Liu F, Wright S, Goodwin RS, et al (2011b). Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 89: 400-407.
63. Katsidoni V, Kastellakis A, Panagis G (2013). Biphasic effects of Delta9-tetrahydrocannabinol on brain stimulation reward and motor activity. Int J Neuropsychopharmacol 16: 2273-2284.
64. Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, et al (2011). Cannabidiol potentiates Delta(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 218: 443-457.
65. Kleinloog D, Liem-Moolenaar M, Jacobs G, Klaassen E, de Kam M, Hijman R, et al (2012). Does olanzapine inhibit the psychomimetic effects of {Delta}9-tetrahydrocannabinol J Psychopharmacol 26: 1307-1316.
66. Kolikonda MK, Kavitha Srinivasan ME, Sagi V, Lippmann S (2016). Medical marijuana for epilepsy Innov Clin Neurosci 13: 23.
67. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172: 4790-4805.
68. Lefever TW, Marusich JA, Antonazzo KR, Wiley JL (2014). Evaluation of WIN 55, 212-2 self-administration in rats as a potential cannabinoid abuse liability model. Pharmacol Biochem Behav 118: 30-35.
69. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2: E94
70. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000). Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 66: 175-181.
71. Leweke M, Kampmann C, Radwan M, Dietrich DE, Johannes S, Emrich HM, et al (1998). The effects of tetrahydrocannabinol on the recognition of emotionally charged words: An analysis using event-related brain potentials. Neuropsychobiology 37: 104-111.
72. Li Q, Yan H, Wilson WA, Swartzwelder HS (2010). Modulation of NMDA and AMPAmediated synaptic transmission by CB1 receptors in frontal cortical pyramidal cells. Brain Res 1342: 127-137.
73. Lichtman AH, Dimen KR, Martin BR (1995). Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 119: 282-290.
74. Lichtman AH, Peart J, Poklis JL, Bridgen DT, Razdan RK, Wilson DM, et al (2000). Pharmacological evaluation of aerosolized cannabinoids in mice. Eur J Pharmacol 399: 141-149.
75. Lichtman AH, Poklis JL, Poklis A, Wilson DM, Martin BR (2001). The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend 63: 107-116.
76. Lichtman AH, Varvel SA, Martin BR (2002). Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 66: 269-285.
77. Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, et al (2010). Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 24: 1697-1708.
78. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, et al (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318: 1375-1387.
79. Maa E, Figi P (2014). The case for medical marijuana in epilepsy. Epilepsia 55: 783-786.
80. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM (2010). Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol 159: 950-957.
81. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, et al (2011). Nonpsychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol 162: 584-596.
82. Malone DT, Jongejan D, Taylor DA (2009). Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 93: 91-96.
83. Manwell LA, Ford B, Matthews BA, Heipel H, Mallet PE (2014). A vapourized Deltatetrahydrocannabinol (Delta-THC) delivery system. Part II: Comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents. J Pharmacol Toxicol Methods 70: 112-119.
84. Marinol (package insert) (2017). AbbVie Inc.: North Chicago, IL, USA, 2017.
85. Marks DF, MacAvoy MG (1989). Divided attention performance in cannabis users and non-users following alcohol and cannabis separately and in combination. Psychopharmacology 99: 397-401.
86. Marsicano G, Lafenetre P (2009). Roles of the endocannabinoid system in learning and memory. Curr Top Behav Neurosci 1: 201-230.
87. Martin WJ, Tsou K, Walker JM (1998). Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 242: 33-36.
88. Matsuzaki M, Casella GA, Ratner M (1987). delta 9-Tetrahydrocannabinol: EEG changes, bradycardia and hypothermia in the rhesus monkey. Brain Res Bull 19: 223-229.
89. McMahon LR (2016). Enhanced discriminative stimulus effects of Delta(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys. Drug Alcohol Depend 165: 87-93.
90. McMahon LR, Amin MR, France CP (2005). SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys. Behav Pharmacol 16: 363-372.
91. McPartland JM, Duncan M, Di Marzo V, Pertwee R (2014). Are cannabidiol and 9-tetrahydrocannabivarin negative modulators of the endocannabinoid system A systematic review. Br J Pharmacol 172: 737-753.
92. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
93. Mechoulam R, Parker LA, Gallily R (2002). Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol 42(11 Suppl): 11S-19S.
94. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (2007). Cannabidiol-recent advances. Chem Biodivers 4: 1678-1692.
95. Mechoulam R, Shani A, Edery H, Grunfeld Y (1970). Chemical basis of hashish activity. Science 169: 611-612.
96. Meier MH, Caspi A, Ambler A, Harrington HL, Houts R, Keefe RSE, et al (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci 109: E2657-E2664.
97. Metna-Laurent M, Mondesir M, Grel A, Vallee M, Piazza PV (2017). Cannabinoidinduced tetrad in mice. Curr Protoc Neurosci 80: 9.59.1-9.59.10.
98. Miller LL, McFarland D, Cornett TL, Brightwell D (1977). Marijuana and memory impairment: Effect on free recall and recognition memory. Pharmacol Biochem Behav 7: 99-103.
99. Mokrysz C, Landy R, Gage SH, Munafo MR, Roiser JP, Curran HV (2016). Are IQ and educational outcomes in teenagers related to their cannabis use A prospective cohort study. J Psychopharmacol 30: 159-168.
100. Morgan CJ, Curran HV (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192: 306-307.
101. Morgan CJ, Freeman TP, Schafer GL, Curran HV (2010a). Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35: 1879-1885.
102. Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, et al (2012). Sub-chronic impact of cannabinoids in street cannabis on cognition, psychoticlike symptoms and psychological well-being. Psychol Med 42: 391-400.
103. Morgan CJ, Schafer G, Freeman TP, Curran HV (2010b). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study: Naturalistic study [corrected]. Br J Psychiatry 197: 285-290.
104. Morrison PD, Stone JM (2011). Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. Hum Psychopharmacol 26: 77-80.
105. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, et al (2009). The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39: 1607-1616.
106. Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, et al (2005). Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit 27: 799-810.
107. Nardo M, Casarotto PC, Gomes FV, Guimaraes FS (2014). Cannabidiol reverses the mCPP-induced increase in marble-burying behavior. Fundam Clin Pharmacol 28: 544-550.
108. Nguyen JD, Aarde SM, Vandewater SA, Grant Y, Stouffer DG, Parsons LH, et al (2016). Inhaled delivery of Delta(9)-tetrahydrocannabinol (THC) to rats by e-cigarette vapor technology. Neuropharmacology 109: 112-120.
109. O'Connell BK, Gloss D, Devinsky O (2017). Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav 70: 341-348.
110. Onaivi ES, Ishiguro H, GONG JP, Patel S, Perchuk A, Meozzi PA, et al (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci 1074: 514-536.
111. Panlilio LV, Justinova Z, Goldberg SR (2010). Animal models of cannabinoid reward. Br J Pharmacol 160: 499-510.
112. Parsons LH, Hurd YL (2015). Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci 16: 579-594.
113. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
114. Pertwee RG (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
115. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998). Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: PL1-PL6.
116. Ranganathan M, D'Souza DC (2006). The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology 188: 425-444.
117. Reche I, Fuentes JA, Ruiz-Gayo M (1996). A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice. Eur J Pharmacol 301: 75-81.
118. Reid MJ, Bornheim LM (2001). Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochem Pharmacol 61: 1357-1367.
119. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Correa FM, Guimaraes FS (2009). 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156: 181-188.
120. Russo E, Guy GW (2006). A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234-246.
121. Sartim AG, Guimaraes FS, Joca SR (2016). Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-possible involvement of 5-HT1A and CB1 receptors. Behav Brain Res 303: 218-227.
122. Schneider U, Borsutzky M, Seifert J, Leweke F, Huber T, Rollnik J, et al (2002). Reduced binocular depth inversion in schizophrenic patients. Schizophr Res 53: 101-108.
123. Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, et al (2011). A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 26: 224-236.
124. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP (2011). Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130: 216-221.
125. Smirnov MS, Kiyatkin EA (2008). Behavioral and temperature effects of delta 9-tetrahydrocannabinol in human-relevant doses in rats. Brain Res 1228: 145-160.
126. Spaderna M, Addy PH, D'Souza DC (2013). Spicing thing up: Synthetic cannabinoids. Psychopharmacology 228: 525.
127. Stadelmann AM, Juckel G, Arning L, Gallinat J, Epplen JT, Roser P (2011). Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. Neurosci Lett 496: 60-64.
128. Stern CA, Gazarini L, Takahashi RN, Guimaraes FS, Bertoglio LJ (2012). On disruption of fear memory by reconsolidation blockade: Evidence from cannabidiol treatment. Neuropsychopharmacology 37: 2132-2142.
129. Stern CA, Gazarini L, Vanvossen AC, Zuardi AW, Galve-Roperh I, Guimaraes FS, et al (2015). Delta9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption. Eur Neuropsychopharmacol 25: 958-965.
130. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al (1995). 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97.
131. Sulak D, Saneto R, Goldstein B (2017). The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav 70: 328-333.
132. Taffe MA (2012). Delta9-Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys. Neuroscience 201: 125-133.
133. Taffe MA, Creehan KM, Vandewater SA (2015). Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Delta(9)-tetrahydrocannabinol in Sprague-Dawley rats. Br J Pharmacol 172: 1783-1791.
134. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613-623.
135. Todd SM, Arnold JC (2016). Neural correlates of interactions between cannabidiol and Delta(9)-tetrahydrocannabinol in mice: Implications for medical cannabis. Br J Pharmacol 173: 53-65.
136. Tulunay FC, Ayhan IH, Portoghese PS, Takemori AE (1981). Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats. EurJ Pharmacol 70: 219-224.
137. Turkanis SA, Karler R (1986). Cannabidiol-caused depression of spinal motoneuron responses in cats. Pharmacol Biochem Behav 25: 89-94.
138. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, et al (2008). Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 94: 191-198.
139. Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, Lichtman AH, et al (2006). Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 186: 226-234.
140. Vermersch P (2011). Sativex(R) (tetrahydrocannabinol+cannabidiol), an endocannabinoid system modulator: Basic features and main clinical data. Expert Rev Neurother 11(4 Suppl): 15-19.
141. Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH (1998). Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: Antagonist effects of SR 141716A. J Pharmacol Exp Ther 286: 697-703.
142. Wade DT, Robson P, House H, Makela P, Aram J (2003). A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17: 21-29.
143. Wade DT, Vergis E (1999). The short orientation-memory-concentration test: A study of its reliability and validity. Clin Rehabil 13: 164-170.
144. Ward A, Holmes B (1985). Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 30: 127-144.
145. Whitlow CT, Freedland CS, Porrino LJ (2002). Metabolic mapping of the timedependent effects of delta 9-tetrahydrocannabinol administration in the rat. Psychopharmacology (Berl) 161: 129-136.
146. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, et al (2005). CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145: 293-300.
147. Wilson RI, Nicoll RA (2002). Endocannabinoid signaling in the brain. Science 296: 678-682.
148. Winsauer PJ, Lambert P, Moerschbaecher JM (1999). Cannabinoid ligands and their effects on learning and performance in rhesus monkeys. Behav Pharmacol 10: 497-511.
149. Wright MJ Jr, Vandewater SA, Taffe MA (2013). Cannabidiol attenuates deficits of visuospatial associative memory induced by Delta(9) tetrahydrocannabinol. Br J Pharmacol 170: 1365-1373.
150. Zuardi AW, Hallak JE, Crippa JA (2012). Interaction between cannabidiol (CBD) and (9)-tetrahydrocannabinol (THC): Influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl) 219: 247-249.
151. Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, et al (2006). Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 20: 683-686.
152. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995). Antipsychotic effect of cannabidiol. J Clin Psychiatry 56: 485-486.
153. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76: 245-250.
154. Zuardi AW, Teixeira NA, Karniol IC (1984). Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch Int Pharmacodyn Ther 269: 12-19.